Gut Microbiota and Metabonomics (MBS)

China Medical University

Status: Enrolling

Conditions: Metabolomics; Gut Microbiota; Stomach Neoplasms

Treatments: Procedure: Borrmann IV patient specimen collection; Procedure: Healthy control specimen collection; Procedure: Non-Borrmann IV patient specimen collection

Study type: Observational

Funder types: Other

Identifiers

NCT05205187

Metabonomics

Details and patient eligibility

About

To evaluate the correlation between gut microbiota and metabolites in Borrmann type IV gastric cancer; To find the effects of microflora and metabolites on target organs; To detect the mechanism of key flora and metabolite by in vitro and in vivo experiments; To construct models of gut microbiota and metabonomics by machine learning.

Enrollment: 450 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients who sign informed consent.
2. Borrmann classification of gastric cancer is determined by more than 2 pathologists.
3. Patients with BMI 24-28.
4. Karnofsky (KPS) score >80.

Exclusion criteria

1. Patients who take any aspirin, antibiotics, prebiotics, or probiotics within 4 weeks and steroids or immunosuppressants within 6 months prior to specimen collection.
2. Patients who complicate with other malignant tumors.
3. Patients who complicate with diabetes, hypertension, heart disease and infectious diseases.
4. Patients who complicate with inflammatory bowel disease or irritable bowel syndrome.
5. Patients with metastasis.

Trial design

450 participants in 3 patient groups

Healthy group

Description:

Healthy people in the community.

Treatment:

Procedure: Healthy control specimen collection

Non-Borrmann IV group

Description:

Patients with Borrmann types I, II and III gastric cancer.

Treatment:

Procedure: Non-Borrmann IV patient specimen collection

Borrmann IV group

Description:

Patients with Borrmann type IV gastric cancer.

Treatment:

Procedure: Borrmann IV patient specimen collection